File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Scleromyxoedema due to a plasma cell neoplasm: Rapid remission with bortezomib, thalidomide and dexamethasone

TitleScleromyxoedema due to a plasma cell neoplasm: Rapid remission with bortezomib, thalidomide and dexamethasone
Authors
Issue Date2012
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJH
Citation
British Journal Of Haematology, 2012, v. 157 n. 4, p. 411 How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/163477
ISSN
2015 Impact Factor: 5.401
2015 SCImago Journal Rankings: 2.313
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYeung, CKen_US
dc.contributor.authorLoong, Fen_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-05T05:31:48Z-
dc.date.available2012-09-05T05:31:48Z-
dc.date.issued2012en_US
dc.identifier.citationBritish Journal Of Haematology, 2012, v. 157 n. 4, p. 411en_US
dc.identifier.issn0007-1048en_US
dc.identifier.urihttp://hdl.handle.net/10722/163477-
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJHen_US
dc.relation.ispartofBritish Journal of Haematologyen_US
dc.subject.meshAntineoplastic Agents - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshBoronic Acids - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshDexamethasone - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasms, Plasma Cell - Complications - Drug Therapyen_US
dc.subject.meshPyrazines - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshScleromyxedema - Drug Therapy - Etiology - Pathologyen_US
dc.subject.meshThalidomide - Administration & Dosage - Therapeutic Useen_US
dc.titleScleromyxoedema due to a plasma cell neoplasm: Rapid remission with bortezomib, thalidomide and dexamethasoneen_US
dc.typeArticleen_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1365-2141.2012.09088.xen_US
dc.identifier.pmid22429092-
dc.identifier.scopuseid_2-s2.0-84859947943en_US
dc.identifier.volume157en_US
dc.identifier.issue4en_US
dc.identifier.spage411en_US
dc.identifier.isiWOS:000302934900001-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridYeung, CK=7201354123en_US
dc.identifier.scopusauthoridLoong, F=6602794154en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats